Leukocyte Surface Antigen CD47 Market Size, Share, Trends & Forecast

The Leukocyte Surface Antigen Cd47 Market is gaining attention as immunotherapy research expands across oncology and hematology. The market was valued at USD 496.5 million in 2024 and is projected to reach USD 1.5 billion by 2035, representing a CAGR of 10.6% from 2025 to 2035. Increasing investment in targeted cancer therapies and CD47-focused research is supporting this expansion.

CD47 has become an important research target because of its role in immune evasion. Therapeutic approaches designed to interfere with CD47 signaling are being investigated as ways to encourage immune recognition of malignant cells. This has increased interest in antibody-based treatments and other approaches that can potentially improve the effectiveness of cancer immunotherapy.

Product development spans antibodies, small molecules, gene therapies, and combination therapies. Among these categories, antibodies are expected to maintain a leading position because of continuing advances in biotechnology and targeted immunotherapy. Combination therapies are also receiving increasing attention as researchers explore ways to integrate CD47-targeted approaches with other treatment modalities.

Cancer therapy represents the largest application area, with the segment valued at approximately USD 220 million in 2024 and projected to reach USD 600 million by 2035. Cardiovascular, autoimmune, and infectious disease applications are also being investigated, broadening the potential scope of CD47-related research.

The market is further supported by collaborations between biotechnology companies, pharmaceutical organizations, and research institutions. Personalized medicine, biomarker identification, and AI-supported analytics could help researchers better understand treatment response and develop more targeted therapeutic strategies. These developments are expected to keep CD47 research an important area within the evolving biopharmaceutical landscape.

Read More
Lukoon https://lukoon.com